Form 4: InMed Director's Stock Options Expire
Insider Transaction Report
InMed Pharmaceuticals Director Andrew Hull reported the expiration of 14 employee stock options.
Summary
- Andrew Hull, a Director of InMed Pharmaceuticals Inc. (INM), filed a Form 4 statement.
- The filing reports the expiration of 14 employee stock options.
- These options had an exercise price of $1,397.97 per share, converted from C$1,925.00 using an exchange rate of C$1.3770 = $US1.00.
- The options were exercisable from December 16, 2020, and expired on December 15, 2025.
- Following this expiration, Andrew Hull beneficially owns 961 derivative securities directly.
Sentiment
Score: 5
Explanation: The filing is a routine insider transaction report (Form 4) detailing the expiration of stock options. It does not inherently convey positive or negative sentiment regarding the company's operational or financial performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of an insider's equity holdings and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: Provides transparency regarding a director's equity holdings and changes, which is standard for corporate governance.
Key Dates
| Date | Description |
|---|---|
| 12/16/2020 | Date employee stock options became exercisable. |
| 12/15/2025 | Date of earliest transaction (expiration of derivative security). |
| 12/16/2025 | Date the Form 4 was signed and filed. |
Keywords
InMed Pharmaceuticals, INM, Form 4, Insider Trading, Stock Options, Director Holdings, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.